{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T18:24:13Z","timestamp":1794939853051,"version":"4.9.1"},"reference-count":25,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"31","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>To evaluate retlirafusp alfa (an anti\u2013PD-L1\/transforming growth factor-\u03b2 bispecific antibody) plus standard chemotherapy as first-line treatment for unresectable, locally advanced or metastatic, human epidermal growth factor receptor 2 (HER2)\u2013negative gastric or gastroesophageal junction adenocarcinoma in the first-line setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>In this randomized, double-blind (RELIGHT), phase III study, 731 patients with previously untreated, unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma were randomly assigned (1:1) to receive retlirafusp alfa or placebo intravenously every 3 weeks plus capecitabine and oxaliplatin (CAPOX). The primary end point was overall survival (OS), assessed in patients with PD-L1 combined positive score (CPS) \u22655 and the intention-to-treat analysis set.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Retlirafusp alfa plus CAPOX significantly prolonged OS versus placebo plus CAPOX in both patients with PD-L1 CPS \u22655 (median, 16.8 vs 10.4 months; stratified hazard ratio [HR], 0.53 [95% CI, 0.40-0.68]; one-sided\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .0001) and the intention-to-treat analysis set (median, 15.8 vs 11.2 months; stratified HR, 0.66 [95% CI, 0.53-0.81]; one-sided\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .0001). Progression-free survival benefit was observed with retlirafusp alfa plus CAPOX versus placebo plus CAPOX in both patients with PD-L1 CPS \u22655 (median, 7.6\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      5.5 months; stratified HR, 0.52 [95% CI, 0.42 to 0.66]) and the intention-to-treat analysis set (median, 7.0\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      5.5 months; stratified HR, 0.57 [95% CI, 0.48 to 0.69]). Grade \u22653 treatment-related adverse events were generally comparable between patients treated with retlirafusp alfa plus CAPOX (62.6% [228 of 364]) and those treated with placebo plus CAPOX (59.0% [216 of 366]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Retlirafusp alfa plus CAPOX represents a first-line treatment option for unresectable, locally advanced or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma. A key limitation is that chemotherapy alone served as the comparator, given that the study protocol was finalized before PD-1 inhibitor plus chemotherapy became the approved standard-of-care regimen in China.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-25-02933","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:00:40Z","timestamp":1790280040000},"page":"3015-3025","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["First-Line Retlirafusp Alfa Plus Chemotherapy for Human Epidermal Growth Factor Receptor 2\u2013Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Double-Blind, Phase III Study (RELIGHT)"],"prefix":"10.1200","volume":"44","clinical-trial-number":[{"clinical-trial-number":"nct04950322","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4063-9813","authenticated-orcid":false,"given":"Zhi","family":"Peng","sequence":"first","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Gastrointestinal Oncology, Peking University Cancer Hospital &amp; Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jufeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Li","sequence":"additional","affiliation":[{"name":"Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute &amp; Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Third Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaozhong","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Hubei Cancer Hospital, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Jilin Cancer Hospital, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Yang","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Shanxi Cancer Hospital, Taiyuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2248-0370","authenticated-orcid":false,"given":"Jun","family":"Yao","sequence":"additional","affiliation":[{"name":"Oncology Department, The First Affiliated Hospital of Henan University of Science &amp; Technology, Luoyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Oncology Department, The Second Hospital of Anhui Medical University, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8455-8121","authenticated-orcid":false,"given":"Lin","family":"Xie","sequence":"additional","affiliation":[{"name":"Gastrooncology Department, Yunnan Cancer Hospital &amp; Third Affiliated Hospital of Kunming Medical University, Kunming, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xizhi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Oncology Department, Subei People's Hospital of Jiangsu Province, Yangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhao","sequence":"additional","affiliation":[{"name":"Gastrointestinal Surgery, Sichuan Cancer Hospital, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changlu","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Chemotherapy Oncology, Anhui Provincial Cancer Hospital, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingdong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Digestive Diseases 2, Liaoning Cancer Hospital and Institute, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangsheng","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9337-8632","authenticated-orcid":false,"given":"Jun","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shaanxi Provincial People's Hospital, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yigui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Abdominal Oncology, Fujian Provincial Cancer Hospital, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4718-6821","authenticated-orcid":false,"given":"Zhongtao","family":"Zhang","sequence":"additional","affiliation":[{"name":"General Surgery Department, Beijing Friendship Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7973-8416","authenticated-orcid":false,"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Anyang Cancer Hospital, Anyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuoxing","family":"Niu","sequence":"additional","affiliation":[{"name":"Internal Medicine Ward2 (Digestive Internal Medicine), Shandong Cancer Hospital &amp; Institute, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyin","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Chemotherapy Oncology, Anhui Provincial Hospital, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University\/Hunan Cancer Hospital, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6873-8026","authenticated-orcid":false,"given":"Yanhong","family":"Deng","sequence":"additional","affiliation":[{"name":"Oncology Department, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigao","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenliang","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Han","sequence":"additional","affiliation":[{"name":"Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8798-4756","authenticated-orcid":false,"given":"Lin","family":"Shen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Gastrointestinal Oncology, Peking University Cancer Hospital &amp; Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_11_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.004"},{"key":"e_1_3_11_3_2","unstructured":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines_Gastric Cancer. Version 4.2024. August 12 2024. https:\/\/www.nccn.org"},{"key":"e_1_3_11_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00797-2"},{"key":"e_1_3_11_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00515-6"},{"key":"e_1_3_11_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918"},{"key":"e_1_3_11_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078876"},{"key":"e_1_3_11_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00692-6"},{"key":"e_1_3_11_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.024"},{"key":"e_1_3_11_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501"},{"key":"e_1_3_11_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01053-x"},{"key":"e_1_3_11_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02605-9"},{"key":"e_1_3_11_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.05.024"},{"key":"e_1_3_11_14_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0346"},{"key":"e_1_3_11_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.03.023"},{"key":"e_1_3_11_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01601"},{"key":"e_1_3_11_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.28463"},{"key":"e_1_3_11_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03450-4"},{"key":"e_1_3_11_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000965"},{"key":"e_1_3_11_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-618090"},{"key":"e_1_3_11_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0420-1"},{"key":"e_1_3_11_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.6.2022"},{"key":"e_1_3_11_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005977"},{"key":"e_1_3_11_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102164"},{"key":"e_1_3_11_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12244"},{"key":"e_1_3_11_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2319"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-02933","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:00:43Z","timestamp":1793224843000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-02933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,1]]},"references-count":25,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2026,11,1]]}},"alternative-id":["10.1200\/JCO-25-02933"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-02933","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,11,1]]},"assertion":[{"value":"2025-12-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}